TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04600349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identity Oriented Psychotrauma Therapy
Description: The method will be presented to the group at the beginning of the first group session. Then every person from the experimental group will set an Intention connected to the emotional or physical difficulties they experience in their lives. Then the person will choose for every word in their Intention, a representative from the support group who will resonate with that word. The focus of every Intention should be the current illness and the traumatic or stressful events which happened before the disease onset.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
Study: NCT05005598

Intervention type: OTHER
Intervention: catheter dysfunction
Description: prevalence of catheter dysfunction
Study: NCT02246933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PUFA Diet
Description: The 7-day diet will consist of 50% carbohydrate, 15% protein, and 35% fat. 21% of total energy will be poly-unsaturated fatty acids, 9% mono-unsaturated fatty acids, and 5% saturated fatty acids.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Diet
Description: The 7-day diet will consist of 50% carbohydrate, 35% fat, and 15% protein. Furthermore, 7% of total energy will be poly-unsaturated fatty acids, 15% of total energy will be mono-unsaturated fatty acids, and 13% of total energy will be saturated fatty acids.
Study: NCT03904654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Description: MBCT is an evidence-based psychotherapy which combines mindfulness skills with cognitive therapy strategies.
Study: NCT03630848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of Protein on Blastocyst Development
Description: Embryo Development Related to The Protein Concentration
Study: NCT01500980

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. falciparum infection
Description: P. falciparum (NF54 strain) infection delivered by the bites of 12 - 15 infected A. stephensi mosquitos

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. falciparum infection
Description: P. falciparum (NF54 strain) infection delivered by the bites of 12 - 15 infected A. stephensi mosquitos

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: P. falciparum infection
Description: P. falciparum (NF54 strain) infection delivered by the bites of 12 - 15 infected A. stephensi mosquitos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Weekly chloroquine dosing (600 mg loading dose, 300 mg thereafter)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Weekly chloroquine dosing (600 mg loading dose, 300 mg thereafter)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Weekly chloroquine dosing (600 mg loading dose, 300 mg thereafter)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Weekly chloroquine dosing (600 mg loading dose, 300 mg thereafter)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine (45 mg) on day 2 or 3 post ITV infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine (45 mg) on day 2 or 3 (pending results of pilot study) post ITV infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Primaquine (45 mg) on day 2 or 3 (pending results of pilot study) post ITV infection
Study: NCT04030312

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bottle Supplementation--Commercially-Sterilized Donor Human Milk
Description: Supplementation by bottle with 20-calorie-per-ounce commercially-sterilized donor human milk (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bottle Supplementation--Standard Infant Formula
Description: Supplementation by bottle with 20-calorie-per-ounce standard infant formula (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
Study: NCT04398836

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Exclusive Enteral Nutrition
Description: Mulnourished patients will drink an enteral polymeric formula suited to their energy expenditure calculated by 25-30 kcal/kg and at least 1 gr/kg of protein, a minimum of 1500 ml (1500 kcal, 54 gr of protein). The amount of formula to achieve nutritional requirements are based on body weight, but the average intake is of 6-8 cups of formula (36-48 scoops of formula mixed with 1260-1680 ml of water to achieve a concentration of 1 kcal per ml). During this period patients will be guided to avoid eating and drinking anything but the enteral formula. The formula will be supplied to the patients by the investigators. The formula used for this study will be VITAL - suitable for people with disease-related malnutrition and malabsorption. Vital 1.5kcal is peptide-based, nutritionally complete formulation for the dietary management of active phase of Crohn's disease. VITAL includes all the nutritional macro and micronutrients and can serve as a sole source of nutrition.

Intervention type: OTHER
Group type: OTHER
Intervention: High energy / protein diet.
Description: Mulnourished patients will receive a high energy / protein diet.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard nutrition
Description: Well nurished patients will receive a standard nutrition
Study: NCT00771368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: 1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days
Study: NCT01123655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APLA12
Description: Intervention: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APLA12
Description: Intervention: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APLA12
Description: Intervention: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
Study: NCT00843466

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mild, moisturizing hand cleanser
Description: Hand cleanser ingredient list:~Ammonium Lauryl Sulfate, Ammonium Laureth Sulfate, Cocamide MEA, PEG-5 Cocamide Cocamidopropyl Betaine Sodium Lauroyl Sarcosinate Glycerin Petrolatum Soybean Oil Sodium Hydroxypropyl Starch Phosphate Lauric Acid Lauryl Alcohol PEG-14M Guar hydroxypropyl trimonium chloride DMDM Hydantoin; Iodopropynyl Butylcarbamate Etidronic Acid Tetrasodium EDTA Titanium Dioxide Fragrance Sodium Hydroxide Water
Study: NCT04796701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-Home-intervention
Description: x
Study: NCT01719653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MiraLAX
Description: MiraLAX consumed as described in each arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MiraLAX
Description: MiraLAX consumed as described in each arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MiraLAX
Description: MiraLAX consumed as described in each arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gatorade
Description: Gatorade consumed as described in each arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gatorade
Description: Gatorade consumed as described in each arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gatorade
Description: Gatorade consumed as described in each arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MoviPrep
Description: MoviPrep consumed as described in each arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUPREP
Description: SUPREP consumed as described in each arm.
Study: NCT00112749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: A single infusion of 1mg/kg will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Assessment
Description: Medical, psychiatric, and immune evaluation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires
Description: Fatigue Symptom Inventory, Multidimensional Fatigue Symptom Inventory, Hamilton Depression Rating Scale, Beck Depression Inventory II, Hamilton anxiety Rating Scale, Pittsburgh Sleep Quality Index, Brief Pain Inventory, MOS SF-36.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immune Assessment
Description: Proinflammatory cytokines and markers of cytokine activity and lymphocyte subsets and CBC.
Study: NCT04460053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurofilament light protein measurement in Isolated limb perfused patients
Description: A prospective feasibility trial measuring neurofilament light protein in peripheral blood as a biomarker for neurotoxicity after isolated limb perfusion.
Study: NCT04194164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid intake app
Description: Monitor fluid intake and interdialytic weight gain in patients using the fluid app
Study: NCT01566110

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten Free Diet
Description: Subjects assigned to the intervention group will receive a standardized dietary education intervention that will inform subjects and family members of the effects of gluten on the gastrointestinal tract and emphasize the need to adhere to a diet that is gluten-free. This intervention will be delivered by a dietician who is trained in celiac disease and gluten free diet.
Study: NCT04896671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise (running on a treadmill)
Description: Participants in the intervention group join a total of 12 treadmill running sessions, two sessions per week and each session for 30 minutes. In each session, every participant will be trained to run for 30 minutes on a treadmill. According to Exercise and Sports Science Australia (ESSA) exercise intensity guidelines, the intensity of running is suggested to be moderate and vigorous (alternating between the two) in this study.
Study: NCT01880827

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y
Description: Subjects in the intervention group will be divided into two consecutive surgical groups, RYGB or SG. After the surgery, subjects are controlled in hospital ward for approximately three days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIP-infusion
Description: Blood flow and volume during infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIP-infusion
Description: Blood flow and volume during infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP-infusion
Description: Blood flow and volume during infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: Blood flow and volume during infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMS
Description: Blood flow and volume after meal solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMS
Description: Blood flow and volume after meal solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMS
Description: Blood flow and volume after meal solution

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Description: as in RYGS group
Study: NCT00381628

Intervention type: PROCEDURE
Intervention: epithelial cells and blood lymphocyte extraction
Description: Nasal curettage will be performed from each nostril to obtain nasal epithelial cells. Venipuncture will be performed and up to 60-ml of blood will be obtained from which neutrophils will be isolated.

Intervention type: PROCEDURE
Intervention: epithelial cells and blood lymphocyte extraction
Description: Nasal curettage will be performed from each nostril to obtain nasal epithelial cells. Venipuncture will be performed and up to 60-ml of blood will be obtained from which neutrophils will be isolated.

Intervention type: PROCEDURE
Intervention: epithelial cells and blood lymphocyte extraction
Description: Nasal curettage will be performed from each nostril to obtain nasal epithelial cells. Venipuncture will be performed and up to 60-ml of blood will be obtained from which neutrophils will be isolated.

Intervention type: PROCEDURE
Intervention: epithelial cells and blood lymphocyte extraction
Description: Nasal curettage will be performed from each nostril to obtain nasal epithelial cells. Venipuncture will be performed and up to 60-ml of blood will be obtained from which neutrophils will be isolated.
Study: NCT03070873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perigee and Apogee Mesh
Description: The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gynecare Prolift Mesh
Description: The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Surgery
Description: The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
Study: NCT03817281

Intervention type: DEVICE
Intervention: Accuryn Monitoring System
Description: The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
Study: NCT04523012

Intervention type: OTHER
Intervention: Seroprevalence of SARS-CoV-2 infection in patients with HIV infection
Description: On inclusion, after information and collection of the non-objection, a blood sample (D0) will be taken during the assessment of the HIV infection (no unplanned sample will be taken) and a control to determine the appearance or the Persistence of antibodies will be made at M6 and M12 always as part of the assessment of HIV infection.
Study: NCT00000320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine formulation: liquid vs. tablet
Description: random assignment to liquid buprenorphine or tablet buprenorphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine formulation: liquid vs. tablet
Description: random assignment to liquid buprenorphine or tablet buprenorphine
Study: NCT01087060

Intervention type: PROCEDURE
Intervention: partial or radical nephrectomy
Study: NCT03581214

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No oxygen
Description: No facemask, room air only

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: 10Liters/minute oxygen by facemask
Study: NCT01737736

Intervention type: DEVICE
Intervention: Neurokeeper stroke detector
Description: Electrophisoloigcal monitoring
Study: NCT01627665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D->R->C+R
Description: one oral dose DABIGATRAN 300 mg -\> RIVAROXABAN 40 mg -\> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D->R->C+D
Description: one oral dose DABIGATRAN 300 mg -\> RIVAROXABAN 40 mg -\> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R->D->C+D
Description: RIVAROXABAN 40 mg -\> one oral dose DABIGATRAN 300 mg -\> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R->D->C+R
Description: RIVAROXABAN 40 mg -\> one oral dose DABIGATRAN 300 mg -\> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
Study: NCT01892332

Intervention type: DRUG
Group type: OTHER
Intervention: epidural block with lidocaine and fentanyl
Description: The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting concentration of lidocaine was 1.5 % mixed with fentanyl 75 ug. All patients receive 13mL of lidocaine with fentanyl 75ug. The concentration of lidocaine for subsequent patients is determined by the outcome in the previous patient according to up and down sequential allocation in 0.1% increments. In the case of block failure, the concentration of lidocaine was increased by 0.1%.~Conversely, block success resulted in a reduction in concentration by 0.1%.
Study: NCT02342626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dashboard
Description: With the health care provider, subjects will use the decision dashboard to augment the discussion of treatment options.
Study: NCT01931384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophin
Description: luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline intramuscularly on the day of embryo transfer and 5 days after embryo transfer.
Study: NCT01207193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell injection
Description: injection of mesenchymal cells to bone cyst defect
Study: NCT00333528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human butyrylcholinesterase (HuBChE) derived from human plasma
Description: Intramuscular administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Normal saline
Description: Intramuscular administration
Study: NCT01922934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commercial weight loss program
Description: vouchers for Weight Watchers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colorado Weigh
Description: Group behavioral weight loss program

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal replacements
Description: Health Management Resources meal replacement products (shakes and entrees)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obesity pharmacotherapy
Description: Phentermine or phentermine-topiramate (Qsymia)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recreation center passes
Description: 1 year pass to a Denver recreation center
Study: NCT00889304

Intervention type: DEVICE
Intervention: Position HTO system
Description: open wedge high tibial osteotomy
Study: NCT03513952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy of tumor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy of tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy of tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glycosylated Recombinant Human Interleukin-7
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glycosylated Recombinant Human Interleukin-7
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography and Computed Tomography Scan
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography and Computed Tomography Scan
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography and Computed Tomography Scan
Description: Undergo PET/CT
Study: NCT00851149

Intervention type: DEVICE
Intervention: Sangvia blood sampling system
Description: Blood collected from abdominal aortic repair patients are compared against blood collected from total hip replacement patients

Intervention type: DEVICE
Intervention: Sangvia blood sampling system
Description: Blood collected from abdominal aortic repair patients are compared against blood collected from total hip replacement patients